AstraZeneca's Imfinzi-tremelimumab duo flops another late-stage lung cancer trial
admin 21st August 2019 Uncategorised 0AstraZeneca has had high hopes for an immuno-oncology combination of Imfinzi and candidate tremelimumab. But after a high-profile miss last year, the combo has struck out again, this time in previously untreated patients with advanced non-small cell lung cancer—even when their tumors were riddled with mutations.
More: AstraZeneca's Imfinzi-tremelimumab duo flops another late-stage lung cancer trial
Source: fierce